Abstract
Objective To explore the effects of tripterygium glycosides on serum interleukin-6 (IL-6), interleukin-8 (IL-8) and T cell subsets in patients with chronic glomerulonephritis. Methods A total of 102 patients with chronic glomerulonephritis admitted to the hospital between August 2016 and August 2018 were enrolled and divided into a control group and an experimental group according to the single-blind method, with 51 cases in each group. Conventional therapy was carried out in both groups, with tripterygium glycosides given additionally to the experimental group. After 3 months of continuous treatment, the clinical efficacy, serum IL-6, IL-8, T cell subsets, renal function and adverse reactions were compared between the two groups. Results The total effective rate of treatment in the experimental group was higher than that in the control group, and the difference was statistically significant (P 0.05). Conclusions For patients with chronic glomerulonephritis, tripterygium glycosides combined with conventional therapy is with great safety, which can help improve the clinical efficacy, and the patients’ renal function and immune function, and reduce the levels of serum IL-6 and IL-8, without increasing adverse reactions. Key words: Glomerulonephritis; TRIPTERYGIUM WILFORDII; Interleukin-6; Interleukin-8; T-Lymphocyte Subsets
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
